Internal medicine (Tokyo, Japan)
Sofosbuvir/Velpatasvir in Chronic Hepatitis C, Compensated and Decompensated Cirrhosis, and Retreatment Settings.
Hitomi Takada, Nobuharu Tamaki, Hironori Ochi, Nami Mori, Keiji Tsuji, Toshifumi Tada, Shinichiro Nakamura, Junichi Toshimori, Naoki Yoshioka, Hirotaka Arai, Hideki Fujii, Chitomi Hasebe, Toshimitsu Murohisa, Eisuke Okamoto, Masahiko Kondo
Published: 202610.2169/internalmedicine.6497-25
Abstract
Objective Sofosbuvir/velpatasvir (SOF/VEL) has been approved for various stages of hepatitis C virus (HCV) infection; however, real-world data on Japanese patients remain limited. We evaluated the efficacy of SOF/VEL treatment in Japanese patients wi…
Preview only. Read the full abstract at the source